February is upon us, and with a new month comes new opportunities to pick standout stocks. Indeed, many investors may be hopeful that the incredible January we just had (the best for the Nasdaq Composite in more than two decades) can continue.

Of course, timing the market isn't something investors should really aim for (it's time in the market that matters more, as the saying goes), but given the lower valuations 2022 has provided, it's clear that investors are loading up on some beaten-down names.

In the biotech sector, there are plenty of these opportunities right now. Valuations have been hit hard as investors price in higher discount rates into their models. For growth stocks, that has meant significant valuation compression, particularly from the post-pandemic highs many stocks previously enjoyed.

Continue reading

Source Fool.com